Article

Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature

Division of Paediatric Rheumatology, CEREMAI, Hôpital de Bicêtre, University of Paris Sud, Le Kremlin Bicêtre Cedex, France.
Seminars in arthritis and rheumatism (Impact Factor: 3.63). 10/2011; 41(2):265-71. DOI: 10.1016/j.semarthrit.2010.11.003
Source: PubMed

ABSTRACT Familial Mediterranean fever (FMF) is an autosomal-recessive autoinflammatory disorder common in Mediterranean populations. FMF is associated with mutations of the MEFV gene, which encodes pyrin. Functional studies suggest that pyrin is implicated in the maturation and secretion of IL-1. The IL-1 receptor antagonist or anti-IL1 monoclonal antibody may therefore represent a new approach to treat FMF. The aim of this report was to evaluate and discuss treatment of FMF with interleukin-1 targeting drugs.
Electronic mailing lists of French pediatric and adult rheumatologist associations were used to call for FMF patients treated with interleukin-1 antagonists. A search for published FMF patients treated with interleukin-1 targeting drugs was performed by screening PubMed.
Here, we report 7 cases of FMF patients treated with anakinra and/or canakinumab and discuss the clinical situations that may indicate the use of IL-1 blocking agents in FMF. The use of interleukin-1 targeting drugs was beneficial to all patients. The reasons for using interleukin-1 targeting drugs in FMF patients were as follows: (1) incomplete control of disease activity despite colchicine treatment; (2) high serum amyloid A levels despite colchicine treatment; (3) impossibility to use colchicine treatment because of severe side effects; (4) FMF in association with vasculitis.
Interleukin-1 targeting drugs may be good candidates when looking for an alternative or supplementary treatment to colchicine. These observations highlight the need for controlled trials to further evaluate the safety and efficacy of interleukin-1 antagonists in FMF patients.

Download full-text

Full-text

Available from: Véronique Hentgen, Jun 30, 2015
0 Followers
 · 
182 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A rating scale method is used for the subjective evaluation and the rating scale method with fuzzy theory is called fuzzy rating. This paper proposes situation-dependent fuzzy rating based on analogical reasoning which applies analogy to the fuzzy rating considering situations. Proposed method assumes that mapping as analogy exists between situations and that fuzzy sets expressing categories in one situation are obtained by those expressing same categories in another situation and analogical reasoning. The usefulness of the presented method is confirmed by the experiments comparing fuzzy sets obtained by the conventional fuzzy rating with those obtained by the presented method. Similarity and the width of a fuzzy set are used for the comparison. Experimental results show that both fuzzy sets are similar and that the presented method is useful for the situation-dependent fuzzy rating.
    Fuzzy Systems, 2004. Proceedings. 2004 IEEE International Conference on; 08/2004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An expanding spectrum of acute and chronic non-infectious inflammatory diseases is uniquely responsive to IL-1β neutralization. IL-1β-mediated diseases are often called "auto-inflammatory" and the dominant finding is the release of the active form of IL-1β driven by endogenous molecules acting on the monocyte/macrophage. IL-1β activity is tightly controlled and requires the conversion of the primary transcript, the inactive IL-1β precursor, to the active cytokine by limited proteolysis. Limited proteolysis can take place extracellularly by serine proteases, released in particular by infiltrating neutrophils or intracellularly by the cysteine protease caspase-1. Therefore, blocking IL-1β resolves inflammation regardless of how the cytokine is released from the cell or how the precursor is cleaved. Endogenous stimulants such as oxidized fatty acids and lipoproteins, high glucose concentrations, uric acid crystals, activated complement, contents of necrotic cells, and cytokines, particularly IL-1 itself, induce the synthesis of the inactive IL-1β precursor, which awaits processing to the active form. Although bursts of IL-1β precipitate acute attacks of systemic or local inflammation, IL-1β also contributes to several chronic diseases. For example, ischemic injury, such as myocardial infarction or stroke, causes acute and extensive damage, and slowly progressive inflammatory processes take place in atherosclerosis, type 2 diabetes, osteoarthritis and smoldering myeloma. Evidence for the involvement of IL-1β and the clinical results of reducing IL-1β activity in this broad spectrum of inflammatory diseases are the focus of this review.
    European Journal of Immunology 05/2011; 41(5):1203-17. DOI:10.1002/eji.201141550 · 4.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent fever, peritonitis/pleuritis, or arthritis attacks. Patients may have FMF-associated mutations of pyrin. The role of biologics such as anti-tumor necrosis factor (TNF) agents (infliximab, etanercept, adalimumab, golimumab) and anakinra, canakinumab, or rilonacept in the treatment of FMF needs to be clarified. Herein we present reports of three patients (all were positive for HLA B27) with typical spondylitis associated with FMF who were successfully managed with anti-TNF agents, along with a literature review. The patients were a 37-year-old man with concomitant Crohn's disease and amyloidosis who was treated with infliximab (INF, 5 mg/kg for 3 years) and switched to adalimumab (ADA), and two female patients (a 24-year-old and a 31-year-old) with FMF who developed severe spondylitis and who were also treated with ADA. Anti-TNF agents can control FMF attacks quite effectively and they reveal a promising role in the treatment of FMF-associated amyloidosis and spondylitis.
    Modern Rheumatology 05/2011; 21(6):684-90. DOI:10.1007/s10165-011-0463-2 · 2.21 Impact Factor